MedTrace Logo

A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands

NCT02546375 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 87

Last updated 2023-10-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to describe the efficacy and safety of bosutinib in patients with chronic myeloid leukaemia used in a real world setting

Conditions

  • Chronic Myeloid Leukaemia

Interventions

DRUG

Bosutinib

Bosutinib 100mg film-coated tablets; Bosutinib 500mg film-coated tablets Dosage as prescribed at treating institution; (observational study)

Sponsors & Collaborators

  • pH Associates

    collaborator UNKNOWN

  • Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-15
Primary Completion
2017-01-16
Completion
2017-01-16

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02546375 on ClinicalTrials.gov